2023-04-012024-03-312024-03-31false06547415AAYAN MEDICAL IMAGING LIMITED2025-03-2543290falseiso4217:GBPxbrli:pure065474152023-04-01065474152024-03-31065474152023-04-012024-03-31065474152022-04-01065474152023-03-31065474152022-04-012023-03-3106547415bus:SmallEntities2023-04-012024-03-3106547415bus:AuditExempt-NoAccountantsReport2023-04-012024-03-3106547415bus:FullAccounts2023-04-012024-03-3106547415bus:PrivateLimitedCompanyLtd2023-04-012024-03-3106547415core:WithinOneYear2024-03-3106547415core:AfterOneYear2024-03-3106547415core:WithinOneYear2023-03-3106547415core:AfterOneYear2023-03-3106547415core:ShareCapital2024-03-3106547415core:SharePremium2024-03-3106547415core:RevaluationReserve2024-03-3106547415core:OtherReservesSubtotal2024-03-3106547415core:RetainedEarningsAccumulatedLosses2024-03-3106547415core:ShareCapital2023-03-3106547415core:SharePremium2023-03-3106547415core:RevaluationReserve2023-03-3106547415core:OtherReservesSubtotal2023-03-3106547415core:RetainedEarningsAccumulatedLosses2023-03-3106547415core:LandBuildings2024-03-3106547415core:PlantMachinery2024-03-3106547415core:Vehicles2024-03-3106547415core:FurnitureFittings2024-03-3106547415core:OfficeEquipment2024-03-3106547415core:NetGoodwill2024-03-3106547415core:IntangibleAssetsOtherThanGoodwill2024-03-3106547415core:ListedExchangeTraded2024-03-3106547415core:UnlistedNon-exchangeTraded2024-03-3106547415core:LandBuildings2023-03-3106547415core:PlantMachinery2023-03-3106547415core:Vehicles2023-03-3106547415core:FurnitureFittings2023-03-3106547415core:OfficeEquipment2023-03-3106547415core:NetGoodwill2023-03-3106547415core:IntangibleAssetsOtherThanGoodwill2023-03-3106547415core:ListedExchangeTraded2023-03-3106547415core:UnlistedNon-exchangeTraded2023-03-3106547415core:LandBuildings2023-04-012024-03-3106547415core:PlantMachinery2023-04-012024-03-3106547415core:Vehicles2023-04-012024-03-3106547415core:FurnitureFittings2023-04-012024-03-3106547415core:OfficeEquipment2023-04-012024-03-3106547415core:NetGoodwill2023-04-012024-03-3106547415core:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3106547415core:ListedExchangeTraded2023-04-012024-03-3106547415core:UnlistedNon-exchangeTraded2023-04-012024-03-3106547415core:MoreThanFiveYears2023-04-012024-03-3106547415core:Non-currentFinancialInstruments2024-03-3106547415core:Non-currentFinancialInstruments2023-03-3106547415dpl:CostSales2023-04-012024-03-3106547415dpl:DistributionCosts2023-04-012024-03-3106547415core:LandBuildings2023-04-012024-03-3106547415core:PlantMachinery2023-04-012024-03-3106547415core:Vehicles2023-04-012024-03-3106547415core:FurnitureFittings2023-04-012024-03-3106547415core:OfficeEquipment2023-04-012024-03-3106547415dpl:AdministrativeExpenses2023-04-012024-03-3106547415core:NetGoodwill2023-04-012024-03-3106547415core:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3106547415dpl:GroupUndertakings2023-04-012024-03-3106547415dpl:ParticipatingInterests2023-04-012024-03-3106547415dpl:GroupUndertakingscore:ListedExchangeTraded2023-04-012024-03-3106547415core:ListedExchangeTraded2023-04-012024-03-3106547415dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-04-012024-03-3106547415core:UnlistedNon-exchangeTraded2023-04-012024-03-3106547415dpl:CostSales2022-04-012023-03-3106547415dpl:DistributionCosts2022-04-012023-03-3106547415core:LandBuildings2022-04-012023-03-3106547415core:PlantMachinery2022-04-012023-03-3106547415core:Vehicles2022-04-012023-03-3106547415core:FurnitureFittings2022-04-012023-03-3106547415core:OfficeEquipment2022-04-012023-03-3106547415dpl:AdministrativeExpenses2022-04-012023-03-3106547415core:NetGoodwill2022-04-012023-03-3106547415core:IntangibleAssetsOtherThanGoodwill2022-04-012023-03-3106547415dpl:GroupUndertakings2022-04-012023-03-3106547415dpl:ParticipatingInterests2022-04-012023-03-3106547415dpl:GroupUndertakingscore:ListedExchangeTraded2022-04-012023-03-3106547415core:ListedExchangeTraded2022-04-012023-03-3106547415dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-04-012023-03-3106547415core:UnlistedNon-exchangeTraded2022-04-012023-03-3106547415core:NetGoodwill2024-03-3106547415core:IntangibleAssetsOtherThanGoodwill2024-03-3106547415core:LandBuildings2024-03-3106547415core:PlantMachinery2024-03-3106547415core:Vehicles2024-03-3106547415core:FurnitureFittings2024-03-3106547415core:OfficeEquipment2024-03-3106547415core:AfterOneYear2024-03-3106547415core:WithinOneYear2024-03-3106547415core:ListedExchangeTraded2024-03-3106547415core:UnlistedNon-exchangeTraded2024-03-3106547415core:ShareCapital2024-03-3106547415core:SharePremium2024-03-3106547415core:RevaluationReserve2024-03-3106547415core:OtherReservesSubtotal2024-03-3106547415core:RetainedEarningsAccumulatedLosses2024-03-3106547415core:NetGoodwill2023-03-3106547415core:IntangibleAssetsOtherThanGoodwill2023-03-3106547415core:LandBuildings2023-03-3106547415core:PlantMachinery2023-03-3106547415core:Vehicles2023-03-3106547415core:FurnitureFittings2023-03-3106547415core:OfficeEquipment2023-03-3106547415core:AfterOneYear2023-03-3106547415core:WithinOneYear2023-03-3106547415core:ListedExchangeTraded2023-03-3106547415core:UnlistedNon-exchangeTraded2023-03-3106547415core:ShareCapital2023-03-3106547415core:SharePremium2023-03-3106547415core:RevaluationReserve2023-03-3106547415core:OtherReservesSubtotal2023-03-3106547415core:RetainedEarningsAccumulatedLosses2023-03-3106547415core:NetGoodwill2022-04-0106547415core:IntangibleAssetsOtherThanGoodwill2022-04-0106547415core:LandBuildings2022-04-0106547415core:PlantMachinery2022-04-0106547415core:Vehicles2022-04-0106547415core:FurnitureFittings2022-04-0106547415core:OfficeEquipment2022-04-0106547415core:AfterOneYear2022-04-0106547415core:WithinOneYear2022-04-0106547415core:ListedExchangeTraded2022-04-0106547415core:UnlistedNon-exchangeTraded2022-04-0106547415core:ShareCapital2022-04-0106547415core:SharePremium2022-04-0106547415core:RevaluationReserve2022-04-0106547415core:OtherReservesSubtotal2022-04-0106547415core:RetainedEarningsAccumulatedLosses2022-04-0106547415core:AfterOneYear2023-04-012024-03-3106547415core:WithinOneYear2023-04-012024-03-3106547415core:Non-currentFinancialInstrumentscore:CostValuation2023-04-012024-03-3106547415core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-04-012024-03-3106547415core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-04-012024-03-3106547415core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-04-012024-03-3106547415core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-04-012024-03-3106547415core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-04-012024-03-3106547415core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-04-012024-03-3106547415core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-04-012024-03-3106547415core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-04-012024-03-3106547415core:Non-currentFinancialInstrumentscore:CostValuation2024-03-3106547415core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-3106547415core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-3106547415core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-3106547415core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-3106547415core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-3106547415core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-3106547415core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-3106547415core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-3106547415core:Non-currentFinancialInstrumentscore:CostValuation2023-03-3106547415core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-03-3106547415core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-03-3106547415core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-03-3106547415core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-03-3106547415core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-03-3106547415core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-03-3106547415core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-03-3106547415core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-03-3106547415bus:Director12023-04-012024-03-31

AAYAN MEDICAL IMAGING LIMITED

Registered Number
06547415
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2024

AAYAN MEDICAL IMAGING LIMITED
Company Information
for the year from 1 April 2023 to 31 March 2024

Director

ZAMAN-KHAN, Seear

Company Secretary

ZAMAN-KHAN, Shaheen

Registered Address

Suite 125 Kingspark Business Park Centre
152 - 178 Kingston Road
New Malden
KT3 3ST

Registered Number

06547415 (England and Wales)
AAYAN MEDICAL IMAGING LIMITED
Balance Sheet as at
31 March 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets957-
957-
Current assets
Stocks390,56095,000
Debtors477,07347,572
Cash at bank and on hand141,893223,531
309,526366,103
Creditors amounts falling due within one year5(284,446)(344,018)
Net current assets (liabilities)25,08022,085
Total assets less current liabilities26,03722,085
Net assets26,03722,085
Capital and reserves
Called up share capital11
Profit and loss account26,03622,084
Shareholders' funds26,03722,085
The financial statements were approved and authorised for issue by the Director on 25 March 2025, and are signed on its behalf by:
ZAMAN-KHAN, Seear
Director
Registered Company No. 06547415
AAYAN MEDICAL IMAGING LIMITED
Notes to the Financial Statements
for the year ended 31 March 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Straight line (years)
Fixtures and fittings4
Office Equipment3
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
2.Average number of employees

20242023
Average number of employees during the year22
3.Stocks

2024

2023

££
Finished goods90,56095,000
Total90,56095,000
4.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables35,36720,722
Other debtors41,70626,850
Total77,07347,572
5.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables3,0054,133
Taxation and social security7461,651
Other creditors279,195338,234
Accrued liabilities and deferred income1,500-
Total284,446344,018